Cardiology 2013 (Full reference info)

Reference Type: Journal Article
Record Number: 686Author: Connolly, M. and Menown, I. B.
Year: 2013
Title: Key advances in clinical cardiology
Journal: Adv Ther
Volume: 30
Issue: 4
Pages: 369-86
Date: Apr
Short Title: Key advances in clinical cardiology
Alternate Journal: Advances in therapy
ISSN: 1865-8652 (Electronic)
0741-238X (Linking)
DOI: 10.1007/s12325-013-0024-5
Accession Number: 23579862
Keywords: Acute Coronary Syndrome/*therapy
Atrial Fibrillation/*therapy
Cardiology/trends
Heart Failure/*therapy
Humans
Abstract: Multiple key cardiology trials with the potential to change practice or advance understanding have been presented over the past 12 months at international meetings, including the American College of Cardiology (ACC, Chicago, USA, March 2012), European Association for Percutaneous Cardiovascular Interventions (EuroPCR, Paris, France, May 2012), European Society of Cardiology (ESC, Munich, Germany, August 2012), Transcatheter Cardiovascular Therapeutics (TCT, Miami, USA, October 2012), and the American Heart Association (AHA, Los Angeles, USA, November 2012). In this paper, the authors describe and place in clinical context new acute coronary syndrome data, including use of oral antiplatelets and anticoagulants (prasugrel, rivaroxaban, vorapaxar), personalized antiplatelet therapy guided by platelet aggregometry, glucose-insulin-potassium infusion, and changing trends in myocardial infarction. New trial data are also described for interventional cardiology (revascularization in multivessel disease, fractional flow reserve-guided intervention, radial access, bioabsorbable polymer stents, drug-eluting balloons, intraaortic balloon pump use, transcatheter aortic valve implantation), in heart failure (copeptin, angiotensin receptor neprilysin inhibition, aldosterone blockade in diastolic heart failure, biventricular pacing), atrial fibrillation (surgical ablation, antithrombotic strategy after stenting), implantable defibrillator use, and in prevention (renal denervation in hypertension, dalcetrapib, lomitapide, proprotein convertase subtilisin/kexin type 9 in dyslipidemia, insulin glargine/fish oils, and bariatric surgery in diabetes).
Notes: Connolly, Michael
Menown, Ian B A
eng
Review
2013/04/13 06:00
Adv Ther. 2013 Apr;30(4):369-86. doi: 10.1007/s12325-013-0024-5. Epub 2013 Apr 9.
URL: http://www.ncbi.nlm.nih.gov/pubmed/23579862
Author Address: Craigavon Cardiac Centre, Craigavon Hospital, Southern Trust, Northern Ireland, BT63 5QQ, UK.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155